Research published in the journal Viruses confirms the efficacy of Cesarox® Epi against viral pneumonia in in vivo studies.

Cesarox® Epi has demonstrated significant potential as an adjunctive therapy

A major article about our development, the pharmaceutical drug Cesarox® Epi, has been published in the reputable international journal Viruses (Issue 17, 2025). The drug demonstrated its efficacy against viral pneumonias in an in vivo study. Adding Cesarox® Epi to the treatment regimen reduced clinical signs of pneumonia, weight loss, fever, and lung pathology, and also led to a significant increase in survival rates. The study indicated that Cesarox® Epi is a promising supportive therapy for the treatment of viral pneumonia. We invite you to read the article.